A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs AC 430 (Primary)
- Indications Leukaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Ambit Biosciences Corporation
- 09 Feb 2011 New source identified and integrated (NCT01287858).
- 21 Dec 2010 New trial record